Transthyretin targeting siRNA therapeutic - Argo Biopharma
Alternative Names: TTR siRNALatest Information Update: 04 Mar 2024
At a glance
- Originator Argo Biopharma
- Class Eye disorder therapies; Small interfering RNA
- Mechanism of Action Prealbumin expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Stargardt disease; Transthyretin-related hereditary amyloidosis
Most Recent Events
- 20 Feb 2024 Transthyretin targeting siRNA therapeutic - Argo Biopharma is available for licensing as of 20 Feb 2024. https://www.argobiopharma.com/partnering/index.html (Argo Biopharma pipeline, February 2024)
- 20 Feb 2024 Preclinical trials in Stargardt disease in China (Parenteral) prior to February 2024 (Argo Biopharma pipeline, February 2024)
- 20 Feb 2024 Preclinical trials in Transthyretin-related hereditary amyloidosis in China (Parenteral) prior to February 2024 (Argo Biopharma pipeline, February 2024)